Antibiotic prophylaxis for head and neck cancer surgery
- Authors: Guz A.O.1, Fatkullin D.M.1, Garev A.V.1, Zakharov A.S.1, Sokolova M.I.1, Alekseeva A.P.1
-
Affiliations:
- Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
- Issue: Vol 10, No 2 (2020)
- Pages: 54-60
- Section: REVIEW
- Published: 24.07.2020
- URL: https://ogsh.abvpress.ru/jour/article/view/527
- DOI: https://doi.org/10.17650/2222-1468-2020-10-2-54-60
- ID: 527
Cite item
Full Text
Abstract
This review analyzes the research data concerning the problem of antibiotic prophylaxis (ABP) of wound infections after various surgeries for head and neck tumors. In patients with clean wounds, ABP should be used in exceptional cases only (for example, if the patient has any risk factors), otherwise it should be avoided. A short ABP course is recommended for patients with clean-contaminated wounds; however highrisk patients may require a prolonged course. There is some evidence of ABP efficacy in patients with non-contaminated wounds after cervical lymphadenectomy. When choosing a drug for ABP, a doctor should consider the site of surgery and the risk of wound contamination. The optimal drugs after head and neck surgeries include first- and second-generation cephalosporins, ampicillin in combination with sulbactam, metronidazole, and clindamycin. First- and second-generation cephalosporins in combination with metronidazole are preferable, but if the wound is infected with gram-positive bacteria, it is necessary to use clindamycin monotherapy. Reconstructive surgeries with a free flap require a short course of ABP with one of the following combinations: cefazolin + metronidazole, cefuroxime + metronidazole, or ampicillin + sulbactam; if the patient is allergic to beta-lactams, clindamycin can be used. Despite the availability of standard ABP regimens, a surgeon must apply a tailored approach when choosing an ABP regimen for each patient, taking into account risk factors and the volume of surgery.
About the authors
A. O. Guz
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
Email: fake@neicon.ru
ORCID iD: 0000-0002-8164-2261
42 Blukhera St., Chelyabinsk 454087 Russian Federation
D. M. Fatkullin
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
Author for correspondence.
Email: gaba-9@yandex.ru
ORCID iD: 0000-0001-9533-4107
42 Blukhera St., Chelyabinsk 454087 Russian Federation
A. V. Garev
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
Email: fake@neicon.ru
ORCID iD: 0000-0002-1831-3748
42 Blukhera St., Chelyabinsk 454087 Russian Federation
A. S. Zakharov
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
Email: fake@neicon.ru
ORCID iD: 0000-0002-7435-3306
42 Blukhera St., Chelyabinsk 454087 Russian Federation
M. I. Sokolova
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
Email: fake@neicon.ru
42 Blukhera St., Chelyabinsk 454087 Russian Federation
A. P. Alekseeva
Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
Email: fake@neicon.ru
ORCID iD: 0000-0002-6621-0284
42 Blukhera St., Chelyabinsk 454087 Russian Federation
References
Supplementary files


